阿尔茨海默病合并α-突触核蛋白病理患者的脑脊液生物标志物
本研究比较尸检确诊的单纯阿尔茨海默病(AD)与混合AD+α-突触核蛋白(αSyn)患者的脑脊液生物标志物。结果显示,合并αSyn病理的AD患者脑脊液p-tau181、t-tau和神经颗粒素水平较低,而Aβ42无差异;合并αSyn可影响诊断准确性,t-tau/Aβ42比值检测AD(含混合病例)的AUC为0.95。
要点
- AD合并αSyn患者脑脊液p-tau181、t-tau和Ng水平低于单纯AD患者
- Aβ42在AD与AD+αSyn两组间无显著差异
- αSyn累积与p-tau181、t-tau和Ng降低相关,与Aβ42无关
核心结论
- AD中合并αSyn病理与脑脊液p-tau181、t-tau和Ng水平降低相关,并可影响AD患者的诊断准确性。
研究设计与样本
- 纳入神经病理学诊断为AD、混合AD+αSyn和αSyn的患者,以及MMSE≥27且有脑脊液样本的 convenience 非损伤对照。
- 共纳入61例AD、39例混合AD+αSyn、20例αSyn患者和61名对照。
- 采用协方差分析(ANCOVA)检验AD与AD+αSyn间脑脊液Aβ42、p-tau181、t-tau和Ng差异,线性模型检验αSyn累积对生物标志物的影响,ROC曲线和AUC评估诊断准确性。
主要发现
- AD+αSyn组p-tau181(F(1,94)=17,p<2.6e-16)、t-tau(F(1,93)=11,p=0.0004)和Ng(F(1,50)=12,p=0.0004)低于AD组;Aβ42无差异(p=0.44)。
- αSyn累积与p-tau181(β=-0.26,SE=0.092,p=0.0065)、t-tau(β=-0.19,SE=0.092,p=0.041)和Ng(β=-0.2,SE=0.066,p=0.0046)降低相关;αSyn对Aβ42不是显著因素(p=1)。
- t-tau/Aβ42比值检测AD(包括混合AD+αSyn病例)的准确性最高,AUC=0.95(CI 0.92-0.98)。
关键数值与推荐
- AD组中位年龄73岁(IQR=12),MMSE 23(IQR=9),男性49%;AD+αSyn组年龄70岁(IQR=13;p=0.3),MMSE 25(IQR=9.5;p=0.19),男性69%(p=0.077)。
- AD+αSyn组p-tau181、t-tau、Ng水平低于AD组,Aβ42无差异。
- t-tau/Aβ42比值诊断AD(含混合AD+αSyn)的AUC=0.95(CI 0.92-0.98)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: CSF biomarkers β-amyloid 1-42 (Aβ42), phosphorylated tau 181 (p-tau181), total tau (t-tau), and neurogranin (Ng) can diagnose Alzheimer disease (AD) in life. However, it is unknown whether CSF concentrations, and thus their accuracies, are affected by concomitant pathologies common in AD, such as α-synuclein (αSyn). Our primary goal was to test whether biomarkers in patients with AD are altered by concomitant αSyn. We compared CSF Aβ42, p-tau181, t-tau, and Ng levels across autopsy-confirmed AD and concomitant AD and αSyn (AD + αSyn). Antemortem CSF levels were related to postmortem accumulations of αSyn. Finally, we tested how concommitant AD + αSyn affected the diagnostic accuracy of 2 CSF-based strategies: the amyloid/tau/neurodegeneration (ATN) framework and the t-tau/Aβ42 ratio. METHODS: Inclusion criteria were neuropathologic diagnoses of AD, mixed AD + αSyn, and αSyn. A convenience sample of nonimpaired controls was selected with available CSF and a Mini-Mental State Examination (MMSE) ≥ 27. αSyn without AD and controls were included as reference groups. Analyses of covariance (ANCOVAs) tested planned comparisons were CSF Aβ42, p-tau181, t-tau, and Ng differences across AD and AD + αSyn. Linear models tested how biomarkers were altered by αSyn accumulation in AD, accounting for pathologic β-amyloid and tau. Receiver operating characteristic and area under the curve (AUC), including 95% CI, evaluated diagnostic accuracy. RESULTS: Participants were 61 patients with AD, 39 patients with mixed AD + αSyn, 20 patients with αSyn, and 61 controls. AD had similar median age (73 [interquartile range {IQR} = 12] years), MMSE (23 [IQR = 9]), and sex distribution (male = 49%) compared with AD + αSyn age (70 [IQR = 13] years; p = 0.3), MMSE (25 [IQR = 9.5]; p = 0.19), and sex distribution (male = 69%; p = 0.077). ANCOVAs showed that AD + αSyn had lower p-tau181 (F(1,94) = 17, p < 2.6e-16), t-tau (F(1,93) = 11, p = 0.0004), and Ng levels (F(1,50) = 12, p = 0.0004) than AD; there was no difference in Aβ42 (p = 0.44). Models showed increasing αSyn related to lower p-tau181 (β = -0.26, SE = 0.092, p = 0.0065), t-tau (β = -0.19, SE = 0.092, p = 0.041), and Ng levels (β = -0.2, SE = 0.066, p = 0.0046); αSyn was not a significant factor for Aβ42 (p = 1). T-tau/Aβ42 had the highest accuracy when detecting AD, including mixed AD + αSyn cases (AUC = 0.95; CI 0.92-0.98). DISCUSSION: Findings demonstrate that concomitant αSyn pathology in AD is associated with lower CSF p-tau181, t-tau, and Ng levels and can affect diagnostic accuracy in patients with AD.
引用
- Cousins KAQ, Arezoumandan S, Shellikeri S, et al. CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology. Neurology. 2022. PMID: 36041863. doi:10.1212/WNL.0000000000201202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。